Navtemadlin (KRT-232): A Comprehensive Monograph on a Novel MDM2 Inhibitor for Oncologic Indications

1.0 Executive Summary

Navtemadlin is an investigational, orally bioavailable, small-molecule therapeutic representing a significant advancement in the targeted inhibition of the murine double minute 2 (MDM2) protein. Developed initially by Amgen as AMG-232 and now advanced by Kartos Therapeutics as KRT-232, Navtemadlin is engineered to be a potent and highly selective antagonist of the MDM2-p53 protein-protein interaction. Its mechanism of action is centered on the restoration of the tumor suppressor function of the p53 protein, a critical regulator of cellular homeostasis often referred to as the "guardian of the genome." In malignancies characterized by wild-type TP53 status but dysregulated by MDM2 overexpression, Navtemadlin competitively binds to MDM2, liberating p53 from negative regulation. This leads to p53 stabilization, accumulation, and subsequent transcriptional activation of target genes that orchestrate cell cycle arrest, senescence, and apoptosis in malignant cells.[1]

The clinical development of Navtemadlin has been most pronounced in myelofibrosis (MF), a severe hematologic malignancy with limited treatment options, particularly for patients who are relapsed or refractory (R/R) to Janus kinase (JAK) inhibitors. The landmark Phase III BOREAS trial (NCT03662126) demonstrated that Navtemadlin monotherapy achieved statistically significant and clinically meaningful improvements in key disease endpoints compared to the best available therapy (BAT). Specifically, Navtemadlin nearly tripled the rate of spleen volume reduction (SVR) of at least 35% and doubled the rate of total symptom score (TSS) improvement of at least 50% at 24 weeks.[4]

Beyond symptomatic improvement, Navtemadlin has shown compelling evidence of disease-modifying activity, a critical unmet need in MF. Treatment has been associated with significant reductions in bone marrow fibrosis, circulating CD34+ malignant progenitor cells, and the variant allele frequency (VAF) of driver gene mutations.[7] These findings suggest that Navtemadlin targets the underlying clonal cell population responsible for the disease. The safety profile of Navtemadlin is well-characterized, predictable, and considered manageable. The most common adverse events are on-target effects related to p53 activation in rapidly dividing normal tissues, primarily manifesting as reversible gastrointestinal toxicities (nausea, diarrhea) and hematologic cytopenias (thrombocytopenia, neutropenia).[4] The implementation of an intermittent dosing schedule has been pivotal in establishing a therapeutic window that balances robust efficacy with tolerability.

Having received Orphan Drug and Fast Track designations from regulatory agencies, Navtemadlin is poised to become a first-in-class approved therapy for R/R myelofibrosis. Ongoing and planned clinical trials are exploring its utility in combination with ruxolitinib in earlier lines of MF therapy and its potential in other TP53-wild-type malignancies, positioning Navtemadlin as a transformative agent in oncology.

2.0 Drug Identification and Physicochemical Properties

This section provides a definitive summary of Navtemadlin's nomenclature, standard identifiers, and fundamental chemical and physical properties that govern its formulation, stability, and biological activity.

2.1 Nomenclature and Identifiers

Navtemadlin is identified by a consistent set of names and codes across scientific literature and regulatory databases, ensuring unambiguous reference.

• Generic Name: Navtemadlin [10]
• Synonyms and Developmental Codes: The drug is widely known by its developmental codes from its originators and current developer: AMG-232, KRT-232, and CS-1300.[2]
• IUPAC Name: 2--2-oxopiperidin-3-yl]acetic acid [10]
• Standard Identifiers:
• DrugBank ID: DB15299 [10]
• CAS Number: 1352066-68-2 [10]
• PubChem CID: 58573469 [10]
• UNII: 7R7G6EH5UL [10]
• ChEMBL ID: CHEMBL3125702 [10]
• KEGG ID: D12378 [10]

2.2 Chemical Structure and Properties

Navtemadlin is a synthetic small molecule designed through a structure-based approach to optimize its interaction with the MDM2 protein.

• Drug Type: Small Molecule [11]
• Chemical Formula: C28​H35​Cl2​NO5​S [10]
• Molecular Weight: The average molecular weight is 568.55 g/mol, with a monoisotopic mass of 567.1612998 Da.[11]
• Chemical Class: Navtemadlin is a complex molecule classified as an acetic acid, piperidine, chlorobenzene, and sulfone derivative. It also belongs to the broader classes of antineoplastic agents and stilbenes.[11]
• Physical Properties:
• Appearance: Solid [12]
• Melting Point: 160–164°C [12]
• Relative Density: 1.254 g/cm³ [12]
• Water Solubility: Predicted to be extremely low at 0.000274 mg/mL, indicating it is practically insoluble in aqueous media.[11]
• Lipophilicity (logP): Predicted values range from 4.27 to 5.86, signifying high lipophilicity and a preference for lipid environments over aqueous ones.[11]
• Acidity (pKa): The strongest acidic pKa is 4.19, attributed to the carboxylic acid functional group.[11]
• Stability: The compound is stable as a solid powder under recommended storage conditions (e.g., -20°C for up to 3 years).[12] However, it is noted to be unstable in solution, necessitating the fresh preparation of solutions for experimental use.[19]

The physicochemical profile of Navtemadlin has profound implications for its development and clinical application. The combination of very low aqueous solubility and high lipophilicity is a classic hallmark of a Biopharmaceutics Classification System (BCS) Class II compound. For such molecules, oral absorption is typically limited not by their ability to cross cell membranes (permeability) but by the rate at which they can dissolve in the gastrointestinal fluids. This dissolution-rate-limited absorption often leads to pharmacokinetic variability and susceptibility to food effects, where the presence of fats and bile salts in the gut can enhance solubilization and increase drug exposure. This fundamental chemical nature directly informed the clinical development path, making it necessary to conduct a dedicated clinical study [20] to precisely characterize the impact of food and formulation changes on Navtemadlin's pharmacokinetic profile, ensuring consistent and predictable dosing for patients.[20]

3.0 Pharmacology and Mechanism of Action

The therapeutic activity of Navtemadlin is rooted in its precise modulation of the p53-MDM2 signaling axis, a central pathway in cancer biology. Its exceptional potency and selectivity for its molecular target are the foundation of both its efficacy and its characteristic safety profile.

3.1 The p53-MDM2 Axis as a Therapeutic Target

The tumor suppressor protein p53 is a transcription factor that plays a pivotal role in maintaining genomic integrity. In response to cellular stress, such as DNA damage or oncogene activation, p53 is activated and orchestrates a range of cellular responses, including transient cell cycle arrest to allow for DNA repair, or permanent arrest (senescence) or programmed cell death (apoptosis) to eliminate irreparably damaged cells.[2] Due to this critical function, the

TP53 gene is the most frequently mutated gene in human cancers.

However, in a substantial subset of cancers, the p53 protein itself is wild-type (TP53-WT) but its function is abrogated by other mechanisms. The primary negative regulator of p53 is the murine double minute 2 (MDM2) protein.[3] MDM2 is an E3 ubiquitin-protein ligase that physically binds to p53, performing two key inhibitory functions: first, it targets p53 for ubiquitination and subsequent degradation by the proteasome, thereby keeping cellular p53 levels low; second, it binds to the transactivation domain of p53, directly blocking its ability to activate the transcription of its target genes.[2] In many

TP53-WT tumors, such as certain sarcomas, leukemias, and myelofibrosis, the MDM2 gene is amplified or the protein is overexpressed, effectively silencing p53 function and allowing cancer cells to proliferate unchecked.[3] This creates a clear therapeutic vulnerability: inhibiting the MDM2-p53 interaction in these tumors can reactivate the endogenous p53 pathway, representing a powerful anti-cancer strategy.[2]

3.2 Molecular Interaction and Binding Kinetics

Navtemadlin was developed through structure-based drug design to be a potent and competitive inhibitor of the MDM2-p53 protein-protein interaction (PPI).[2] It functions by occupying the deep hydrophobic cleft on the surface of the MDM2 protein that is the natural binding site for the p53 transactivation domain. By physically blocking this site, Navtemadlin prevents MDM2 from binding to and inhibiting p53.[13]

The potency of this interaction is exceptionally high, as quantified by multiple biophysical and biochemical assays:

• Target: E3 ubiquitin-protein ligase Mdm2 (UniProt ID: Q00987).[11]
• Binding Affinity (Kd): Navtemadlin binds to MDM2 with a dissociation constant (Kd​) of 0.045 nM, indicating picomolar affinity.[19]
• Inhibitory Concentration (IC50): It inhibits the MDM2-p53 interaction in biochemical assays with a half-maximal inhibitory concentration (IC50​) of 0.6 nM.[16]
• Cellular Potency: This high affinity translates to potent activity in cancer cells. In TP53-WT cell lines such as the MDM2-amplified SJSA-1 osteosarcoma line and the non-amplified HCT116 colorectal cancer line, Navtemadlin inhibits cell growth with IC50​ values of 9.1 nM and 10 nM, respectively.[13]

A critical feature of Navtemadlin is its selectivity. Affinity-based protein profiling experiments using photoactivatable probes have robustly confirmed that MDM2 is the primary and dominant molecular target in cancer cells, with minimal engagement of other proteins.[1] The drug shows no significant activity against other MDM family members at concentrations up to 10 µM and has negligible off-target activity against a large panel of kinases, underscoring its highly targeted nature.[26]

3.3 Downstream Pharmacodynamic Effects

By effectively uncoupling p53 from MDM2-mediated degradation and inhibition, Navtemadlin triggers a cascade of downstream events consistent with p53 pathway activation.[2] The immediate consequence is the rapid stabilization and accumulation of p53 protein within the tumor cell. This activated p53 then functions as a transcription factor, binding to the promoter regions of its target genes and upregulating their expression.[25]

Key p53 target genes induced by Navtemadlin include:

• CDKN1A (p21): A potent cyclin-dependent kinase inhibitor that enforces cell cycle arrest, primarily at the G1/S and G2/M checkpoints.[13]
• MDM2: p53 upregulates its own inhibitor, MDM2, in a classic negative feedback loop. This can be observed as an increase in MDM2 mRNA and protein levels following Navtemadlin treatment.[23]
• BBC3 (PUMA): A pro-apoptotic BH3-only protein that is a critical mediator of p53-induced apoptosis.[23]

The integrated cellular outcomes of this transcriptional program are profound: tumor cells undergo cell cycle arrest and apoptosis, leading to a potent inhibition of proliferation and, in preclinical models, durable tumor regression.[2] This anti-tumor activity is strictly dependent on a functional, wild-type p53 protein. In cell lines where

TP53 is mutated or deleted, Navtemadlin shows no significant effect on cell growth, confirming its on-target mechanism of action.[13]

3.4 Biomarkers of Target Engagement

The activation of the p53 pathway by Navtemadlin leads to measurable changes in downstream biomarkers that can be monitored in patients to confirm target engagement and pharmacodynamic activity. The most well-validated of these is Macrophage Inhibitory Cytokine-1 (MIC-1), also known as Growth Differentiation Factor-15 (GDF15). MIC-1 is a direct transcriptional target of p53. Clinical studies have consistently shown that administration of Navtemadlin leads to a robust, dose- and plasma concentration-dependent increase in serum MIC-1 levels.[20] The time course of MIC-1 induction, with a peak delayed by approximately 8 hours relative to the drug's peak concentration, is consistent with a process involving gene transcription and protein synthesis.[27] This makes MIC-1 an invaluable clinical pharmacodynamic biomarker for verifying that Navtemadlin is effectively engaging MDM2 and activating the p53 pathway in patients.[20]

The highly selective and potent on-target mechanism of Navtemadlin is the cornerstone of its therapeutic potential. However, this specificity is also inextricably linked to its toxicity profile. The p53 protein is a universal regulator of cell fate, and its potent activation is not confined to cancer cells. Rapidly proliferating normal tissues, most notably the hematopoietic progenitors in the bone marrow and the epithelial lining of the gastrointestinal tract, are also highly sensitive to p53-mediated cell cycle arrest and apoptosis. Consequently, the potent reactivation of p53 by Navtemadlin in these tissues is the direct cause of the most common and dose-limiting toxicities observed in clinical trials: hematologic cytopenias (thrombocytopenia, neutropenia) and gastrointestinal disturbances (nausea, vomiting, diarrhea). These adverse events are not off-target effects but rather an expected pharmacologic consequence of the drug's intended mechanism, a factor that has profoundly influenced the development of dosing schedules designed to manage these on-target liabilities.[4]

4.0 Pharmacokinetics and Drug Metabolism

The clinical utility of Navtemadlin is underpinned by a pharmacokinetic (PK) profile that allows for convenient oral administration and sustained target engagement. Its absorption, distribution, metabolism, and excretion (ADME) properties have been characterized in preclinical species and extensively in humans across multiple clinical trials.

4.1 Absorption, Distribution, Metabolism, and Excretion (ADME) Profile in Humans

Navtemadlin exhibits predictable PK properties that support a once-daily, intermittent dosing schedule.

• Administration and Absorption: Navtemadlin is an orally available drug that displays first-order absorption kinetics.[10] Following oral administration, the mean time to reach maximum plasma concentration ( Tmax​) is typically between 2 and 4 hours.[20] A notable feature in the concentration-time profiles is the appearance of a second distinct peak at approximately 10 hours post-dose, which is strong evidence of enterohepatic recirculation (EHR), a process where the drug is excreted into the bile, reabsorbed in the intestine, and returned to systemic circulation.[27]
• Distribution: The distribution of Navtemadlin is best described by a two-compartment population PK model.[27] It distributes extensively into tissues, as indicated by its large apparent volumes of distribution. In cancer patients, the apparent oral central volume of distribution ( Vc​/F) is approximately 62.9 L, and the apparent peripheral volume (Vp​/F) is 333 L.[20] The drug is also highly bound to plasma proteins (97.5%), which influences its distribution and availability to target tissues.[31]
• Metabolism: The primary route of elimination for Navtemadlin is biotransformation.[31] Preclinical and in vitro human studies identified the major metabolic pathway as glucuronidation, resulting in the formation of an acyl glucuronide metabolite, designated M1.[20] This metabolite has been shown to be approximately 5-fold less pharmacologically active than the parent compound.[27] In humans, the parent drug remains the dominant active moiety, with the mean metabolite-to-parent area under the curve (AUC) ratio being relatively low, at 0.20 in healthy volunteers and 0.46 in patients with solid tumors.[20]
• Elimination: The apparent oral clearance (CL/F) in patients with solid tumors is estimated to be 24.9 L/h.[20] The terminal elimination half-life ( t1/2​) in humans is consistently reported to be in the range of 17.1 to 18.6 hours.[20] This relatively long half-life is sufficient to support a once-daily dosing regimen. Consistent with metabolism being the main elimination pathway, the excretion of unchanged Navtemadlin in the urine is negligible.[20]

4.2 Pharmacokinetic Linearity and Covariate Analysis

Navtemadlin's pharmacokinetics are predictable across a wide range of doses. Clinical studies have demonstrated that exposure, as measured by AUC, increases in a dose-proportional manner over a dose range of 15 mg to 480 mg, indicating linear pharmacokinetics.[20]

Population PK modeling, which analyzes data from a large and diverse patient population, has identified certain patient characteristics, or covariates, that can influence drug exposure. A significant finding is that patients with acute myeloid leukemia (AML) exhibit a 61.6% greater steady-state AUC compared to patients with solid tumors, suggesting potential differences in drug absorption or clearance between these populations.[30] Furthermore, a correlation was found with serum albumin levels; patients with decreased albumin (e.g., at the 5th percentile of the population) were modeled to have a 47.7% increase in AUC, likely due to reduced plasma protein binding and a higher fraction of unbound, clearable drug.[30]

4.3 Central Nervous System (CNS) Penetration

The pharmacokinetic profile of Navtemadlin reveals a critical dichotomy between its systemic efficacy and its potential for treating CNS malignancies. While its systemic exposure is robust, its ability to cross the blood-brain barrier (BBB) is severely restricted. Preclinical studies in mice have unequivocally demonstrated that Navtemadlin is a substrate for active efflux transporters at the BBB, particularly P-glycoprotein (P-gp, encoded by the ABCB1 gene).[21] This active pumping of the drug out of the brain results in an extremely low brain-to-plasma concentration ratio (

Kp,brain​) of just 0.009.[21]

The functional consequence of this poor CNS penetration is stark. In orthotopic mouse models of glioblastoma (GBM), where the tumor is grown within the brain, Navtemadlin was completely ineffective even at high doses (100 mg/kg).[21] However, a pivotal experiment using genetically engineered mice lacking the key efflux pumps (

Abcb1a/b and Abcg2) provided definitive proof-of-principle. In these efflux-deficient mice, a much lower dose of Navtemadlin (25 mg/kg) was able to achieve therapeutic concentrations in the brain tumor and significantly extended survival.[21] This demonstrates that the drug is inherently active against GBM cells, but its efficacy is nullified by the delivery barrier.

These preclinical findings were directly translated and confirmed in a Phase 0 "window-of-opportunity" study in human GBM patients. This type of study involves administering the drug to patients shortly before a scheduled surgery, allowing for direct measurement of drug concentrations in the resected tumor tissue. The results showed that at the clinically relevant 240 mg dose, the minimum effective tumor exposures (as determined from preclinical models) were achieved in only a small minority of patients (3 out of 16).[21] This confirmation of inadequate drug delivery to the CNS explains why the clinical development of Navtemadlin for primary brain tumors has not progressed, while its development for systemic diseases like myelofibrosis and other hematologic cancers, where the BBB is not a factor, has advanced successfully.[14] This illustrates how a single pharmacokinetic property can fundamentally dictate a drug's entire clinical development strategy.

5.0 Clinical Development Program

The clinical investigation of Navtemadlin has been extensive, evolving from broad, early-phase exploration across numerous cancer types to a highly focused, late-stage program targeting indications with the strongest biological rationale and clinical signal. This strategic evolution has positioned Navtemadlin for potential regulatory approval in myelofibrosis.

5.1 Overview of Clinical Trials

Navtemadlin has been evaluated as a monotherapy and in combination with other anti-cancer agents in multiple Phase I, II, and III clinical trials. The breadth of this program reflects the foundational importance of the p53-MDM2 pathway across oncology. Table 1 provides a summary of the key clinical trials that have defined its development trajectory.

Table 1: Summary of Key Navtemadlin Clinical Trials

NCT Identifier	Trial Name/Acronym	Phase	Indication(s)	Status (as of latest data)	Key Design/Objectives
NCT03662126	BOREAS	2/3	Relapsed/Refractory Myelofibrosis (R/R MF)	Active, Not Recruiting	Randomized, open-label study of Navtemadlin vs. Best Available Therapy (BAT) 3
NCT06479135	POIESIS	3	JAK Inhibitor-Naïve Myelofibrosis (with suboptimal response)	Recruiting	Randomized, double-blind, add-on study of Navtemadlin vs. Placebo with Ruxolitinib 39
NCT04485260	KRT-232-109	1b/2	Myelofibrosis (with suboptimal response to Ruxolitinib)	Active, Not Recruiting	Open-label study of Navtemadlin added to stable-dose Ruxolitinib 40
NCT03787602	KRT-232-103	1b/2	Merkel Cell Carcinoma (MCC) (post-PD-1/L1)	Active, Not Recruiting	Dose-finding and expansion study of Navtemadlin monotherapy 42
NCT03041688	NCI-2017-00152	1b	Acute Myeloid Leukemia (AML) (R/R or Newly Diagnosed)	Active, Not Recruiting	Dose-escalation study of Navtemadlin + Decitabine + Venetoclax 10
NCT02016729	-	1b	Acute Myeloid Leukemia (AML)	Completed	Study of Navtemadlin alone and in combination with Trametinib 44
NCT01723020	-	1	Advanced Solid Tumors, Multiple Myeloma	Completed	First-in-human dose-escalation and expansion study 45
NCT04113616	KRT-232-104	1b/2	AML secondary to MPN	Active, Not Recruiting	Open-label study evaluating different Navtemadlin dosing schedules 46
NCT03220339	ALLIANCE-ABTC-1604	0	Recurrent Glioblastoma (GBM)	Active, Not Recruiting	Window-of-opportunity study to assess CNS penetration 47

5.2 Hematologic Malignancies

The strongest efficacy signals for Navtemadlin have emerged in hematologic malignancies, particularly myeloproliferative neoplasms (MPNs).

5.2.1 Myelofibrosis (MF)

Myelofibrosis has become the lead indication for Navtemadlin, driven by a strong biological rationale (MDM2 is overexpressed in malignant MF CD34+ cells) and compelling clinical data.[3]

• Pivotal Phase III BOREAS Trial (NCT03662126): This randomized, controlled, open-label study is the cornerstone of the Navtemadlin program. It was designed to evaluate Navtemadlin monotherapy (240 mg daily for days 1-7 of a 28-day cycle) against investigator's choice of BAT in patients with MF who were relapsed or refractory to prior JAK inhibitor therapy—a population with a dismal prognosis.[3]
• Efficacy: Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting demonstrated that the trial met its primary and key secondary endpoints. At week 24, 15% of patients in the Navtemadlin arm achieved a spleen volume reduction of ≥35% (SVR35), compared to just 5% in the BAT arm (a 3-fold increase).[4] Similarly, 24% of Navtemadlin-treated patients achieved a ≥50% reduction in their total symptom score (TSS50), versus 12% in the BAT arm (a 2-fold increase).[4]
• Disease-Modifying Activity: The BOREAS trial provided powerful evidence of Navtemadlin's potential to alter the natural history of the disease. Nearly half of the patients (48%) treated with Navtemadlin experienced an improvement of at least one grade in bone marrow fibrosis, compared to 24% with BAT.[6] Furthermore, treatment led to profound and sustained reductions in circulating CD34+ progenitor cells (a surrogate for the malignant clone) and a ≥50% reduction in driver gene VAF in 21% of patients, nearly double the rate seen with BAT (12%).[7]
• Phase I/II Combination with Ruxolitinib (NCT04485260): Recognizing that many patients experience a suboptimal, rather than complete, loss of response to ruxolitinib, this study evaluated the addition of Navtemadlin to a stable dose of the JAK inhibitor.[40] The results were highly encouraging, showing that the combination could deepen responses. At week 24, 32% of evaluable patients achieved an SVR35 and 32% achieved a TSS50.[9] The combination also produced significant reductions in CD34+ cells (median decrease of -95%) and improved bone marrow fibrosis in 57% of evaluable patients, demonstrating strong synergistic activity.[9]
• Phase III POIESIS Trial (NCT06479135): Building on the success of the combination study, the POIESIS trial represents a strategic move into an earlier treatment setting. This innovative trial enrolls JAK inhibitor-naïve patients, treats them with ruxolitinib, and for those who demonstrate a suboptimal response after an initial run-in period, randomizes them in a double-blind fashion to receive either add-on Navtemadlin or placebo.[39] Success in this trial could establish the Navtemadlin-ruxolitinib combination as a new standard of care for a large segment of first-line MF patients.

5.2.2 Acute Myeloid Leukemia (AML)

Early-phase studies have explored Navtemadlin in AML, where TP53-WT status is common. A Phase Ib study (NCT02016729) evaluated Navtemadlin alone and in combination with the MEK inhibitor trametinib, establishing safety and dose-proportional PK, with some patients achieving stable disease.[33] A subsequent Phase Ib trial (NCT03041688) is investigating a triplet combination of Navtemadlin with decitabine and the BCL-2 inhibitor venetoclax, a modern standard-of-care backbone in AML.[10]

5.2.3 Other Hematologic Cancers

The clinical program has also included a Phase II study in phlebotomy-dependent polycythemia vera (PV) (NCT03669965) [52] and an ongoing Phase Ib/II study in relapsed/refractory Philadelphia chromosome-positive chronic myeloid leukemia (CML) in combination with a tyrosine kinase inhibitor (TKI) (NCT04835584).[53]

The clinical development path of Navtemadlin exemplifies a successful pharmaceutical strategy. An initial broad exploration by the originator, Amgen, across a wide array of cancers identified a particularly strong signal in myelofibrosis. The current developer, Kartos Therapeutics, has astutely capitalized on this by executing a focused and rigorous late-stage program in MF. This strategy of "finding the right drug for the right disease" has propelled Navtemadlin to the cusp of approval and established a clear path for building a franchise around this novel agent, starting with the highest unmet need in the R/R setting and systematically moving into earlier lines of therapy.

5.3 Solid Tumors

While the primary focus has shifted to hematologic cancers, Navtemadlin has also been evaluated in several solid tumor types, with notable activity seen in Merkel cell carcinoma.

5.3.1 Merkel Cell Carcinoma (MCC)

MCC is a rare but aggressive neuroendocrine skin cancer. A Phase Ib/II study (NCT03787602) was designed to evaluate Navtemadlin in patients with TP53-WT MCC whose disease had progressed after treatment with anti-PD-1/L1 immunotherapy.[42] The trial identified a recommended Phase 2 dose and schedule of 180 mg daily for 5 days, followed by 23 days off. In this heavily pretreated population, Navtemadlin monotherapy demonstrated promising and durable anti-tumor activity, achieving a confirmed objective response rate (ORR) of 25% and a disease control rate of 63%. Some responses were remarkably durable, with one patient achieving a complete metabolic remission after two years on treatment, establishing proof-of-concept for MDM2 inhibition in this disease.[42]

5.3.2 Glioblastoma (GBM)

As detailed in the Pharmacokinetics section, the development of Navtemadlin for GBM was halted by a fundamental drug delivery challenge. A Phase 0 window-of-opportunity study confirmed that, due to active efflux by P-glycoprotein at the blood-brain barrier, therapeutically relevant concentrations of Navtemadlin could not be achieved in the majority of patients' brain tumors.[21] This finding, while disappointing, provided a clear, data-driven rationale to discontinue development in this indication and focus resources on systemic cancers where the drug could reliably reach its target.

5.3.3 Other Solid Tumors

Navtemadlin's clinical journey began with a first-in-human Phase I study (NCT01723020) that included patients with a variety of advanced solid tumors and multiple myeloma, which successfully established the drug's safety profile and recommended dose.[13] Other explorations have included a trial in soft tissue sarcoma combined with radiation therapy [54] and an ongoing Phase II study in

TP53-WT relapsed/refractory small cell lung cancer (SCLC).[55]

6.0 Safety and Tolerability Profile

The safety profile of Navtemadlin has been extensively characterized across numerous clinical trials involving hundreds of patients. The observed adverse events are largely predictable, manageable, and consistent with the drug's on-target mechanism of p53 activation in rapidly dividing normal tissues.

6.1 Integrated Analysis of Adverse Events

Navtemadlin has demonstrated an acceptable and manageable safety profile, with the majority of treatment-emergent adverse events (TEAEs) being Grade 1 or 2 in severity and reversible upon cessation of dosing.[4] The most frequently reported and clinically significant toxicities fall into two main categories: gastrointestinal and hematologic. The combination of Navtemadlin with ruxolitinib in myelofibrosis patients appears to be well-tolerated, with a safety profile generally consistent with that of each agent alone.[9] Table 2 summarizes the incidence of common TEAEs from key myelofibrosis trials.

Table 2: Incidence of Common Treatment-Emergent Adverse Events (TEAEs) in Myelofibrosis Trials

Adverse Event	Navtemadlin Monotherapy (BOREAS) 4	Navtemadlin + Ruxolitinib (NCT04485260) 9
	Any Grade (%)	Grade ≥3 (%)
Gastrointestinal
Nausea	42	4
Diarrhea	41	6
Vomiting	25	2
Hematologic
Thrombocytopenia	46	37
Anemia	36	29
Neutropenia	30	25
Constitutional
Fatigue/Asthenia	N/A	N/A

6.2 Characterization of Key Toxicities

The on-target nature of Navtemadlin's adverse events allows for proactive monitoring and management.

• Gastrointestinal (GI) Toxicity: Nausea, diarrhea, and vomiting are the most common non-hematologic side effects.[4] In the BOREAS trial, these events were predominantly Grade 1 or 2. A key clinical observation is their temporal pattern: they typically have a rapid onset within the 7-day dosing period (median onset 4-8 days) and are transient, with a median time to resolution of about one week.[4] This predictability allows for effective management with standard supportive care, such as prophylactic antiemetics.[24]
• Hematologic Toxicity: The most common Grade 3/4 adverse events are hematologic, including thrombocytopenia, anemia, and neutropenia.[4] These cytopenias are a direct result of p53-mediated cell cycle arrest and apoptosis in hematopoietic stem and progenitor cells. Similar to the GI effects, these toxicities are predictable and reversible. Data from the BOREAS study show a median time to onset of approximately 29-30 days for these events, with median times to resolution of 8-14 days.[4] The reversibility of these cytopenias during the "off-drug" period is crucial for the long-term tolerability of the treatment.

6.3 Dose-Limiting Toxicities (DLTs) and Recommended Phase II Dose (RP2D)

In the initial Phase I dose-escalation studies, dose-limiting toxicities (DLTs) were encountered at higher dose levels. Specifically, Grade 3/4 thrombocytopenia and neutropenia were identified as DLTs at doses of 360 mg and 480 mg administered daily for 7 days.[13] These findings were instrumental in guiding dose selection for later-phase studies. The 240 mg daily dose for 7 days in a 28-day cycle was selected as the Recommended Phase 2 Dose (RP2D) for the pivotal BOREAS study, as it was determined to provide a favorable balance between robust anti-tumor efficacy and a manageable safety profile.[13]

The successful clinical application of Navtemadlin hinges on its dosing schedule. The potent, on-target mechanism would likely lead to unacceptable cumulative toxicity if administered continuously. The intermittent schedule (e.g., 7 days on, 21 days off) is a critical design feature that creates the therapeutic window. The 7-day "on" period is sufficient to exert a powerful apoptotic effect on malignant cells, as evidenced by the efficacy data. The subsequent 21-day "off" period allows the normal, healthy bone marrow and gastrointestinal tissues to recover from the transient p53-induced stress. This "pulsed" therapeutic approach is a sophisticated application of pharmacodynamic principles that effectively manages the on-target liabilities of the drug, enabling its long-term administration and unlocking its clinical potential.

7.0 Regulatory Landscape and Future Directions

Navtemadlin is an investigational agent that has not yet received marketing approval from any regulatory agency. However, its promising clinical data in areas of high unmet medical need have earned it several special designations that are intended to facilitate and expedite its development and review.

7.1 Regulatory Designations

Navtemadlin's potential has been recognized by key global health authorities:

• U.S. Food and Drug Administration (FDA):
• Orphan Drug Designation: Granted for the treatment of Merkel cell carcinoma on April 8, 2020.[56]
• Orphan Drug Designation: Granted for the treatment of myelofibrosis.[13]
• Fast Track Designation: Granted for the treatment of JAK inhibitor relapsed/refractory myelofibrosis, a designation designed to accelerate the review of drugs that treat serious conditions and fill an unmet medical need.[24]
• European Medicines Agency (EMA):
• Orphan Designation: Granted for the treatment of Merkel cell carcinoma on January 14, 2022.[10]

These designations provide benefits such as protocol assistance, reduced fees, and potential market exclusivity upon approval, highlighting the regulatory support for Navtemadlin's development.

7.2 Comparative Landscape and Concluding Remarks

The therapeutic strategy of inhibiting the MDM2-p53 interaction has been pursued for over two decades, but the clinical development of MDM2 inhibitors has been challenging. Early candidates like Nutlin-3a had poor pharmacokinetic properties, and other clinical-stage molecules, such as Idasanutlin (RG7388), have faced setbacks in pivotal trials.[58] The field has been hampered by a narrow therapeutic window, with on-target hematologic and GI toxicities often limiting the ability to achieve durable anti-tumor responses with monotherapy.[58] In this context, the positive results of the Phase III BOREAS trial are a landmark achievement, not only for Navtemadlin but for the entire class of MDM2 inhibitors. It provides the first robust, large-scale validation of this mechanism as a viable and effective single-agent therapy in a well-defined patient population.

The future direction for Navtemadlin is clearly defined. The immediate goal is to secure regulatory approval for the treatment of relapsed/refractory myelofibrosis based on the BOREAS data, which would establish it as the first non-JAK inhibitor therapy to demonstrate significant efficacy in this setting. The long-term strategy involves expanding its role within the MF treatment paradigm. The ongoing POIESIS study is a critical step in this direction, evaluating if adding Navtemadlin to ruxolitinib in the first-line setting for patients with a suboptimal response can improve outcomes and potentially change the standard of care.[6] Continued development in other

TP53-WT malignancies with a strong biological rationale, such as Merkel cell carcinoma and small cell lung cancer, also remains a key area of interest.

In conclusion, Navtemadlin has progressed from a highly potent molecular entity to a late-stage clinical asset with proven efficacy and manageable safety in a disease with dire need for new therapies. Its success is a testament to the power of targeted drug development, the importance of understanding on-target toxicity, and the strategic implementation of dosing schedules and clinical trial designs to create a viable therapeutic window. Pending regulatory approval, Navtemadlin is poised to offer a novel, disease-modifying treatment option for patients with myelofibrosis and represents a significant validation of the MDM2-p53 axis as a druggable target in oncology.

Works cited

1. Affinity-based protein profiling of MDM2 inhibitor Navtemadlin - RSC Publishing, accessed September 7, 2025, https://pubs.rsc.org/en/content/articlelanding/2025/sc/d5sc00120j
2. Affinity-based protein profiling of MDM2 inhibitor Navtemadlin - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11921932/
3. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/36416118/
4. Contributor: A Crisis in Public Health—Addressing the Exodus From ..., accessed September 7, 2025, https://www.targetedonc.com/view/navtemadlin-monotherapy-shows-safety-efficacy-in-r-r-myelofibrosis
5. Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis - CancerNetwork, accessed September 7, 2025, https://www.cancernetwork.com/view/navtemadlin-shows-efficacy-safety-in-relapsed-refractory-myelofibrosis
6. BOREAS Trial Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis - The ASCO Post, accessed September 7, 2025, https://ascopost.com/issues/february-25-2025/boreas-trial-navtemadlin-demonstrates-clinical-benefit-in-jak-inhibitor-refractory-myelofibrosis/
7. New Clinical Trial Treatment Causes Myelofibrosis Cell Death - HealthTree Foundation, accessed September 7, 2025, https://healthtree.org/myelofibrosis/community/articles/ash-24-navtemadlin-myelofibrosis-boreas-trial
8. Navtemadlin Monotherapy Shows Improvements in Hallmarks of R/R Myelofibrosis, accessed September 7, 2025, https://www.targetedonc.com/view/navtemadlin-monotherapy-shows-improvements-in-hallmarks-of-r-r-myelofibrosis
9. Navtemadlin Elicits Spleen Volume Reduction When Added to ..., accessed September 7, 2025, https://www.onclive.com/view/navtemadlin-elicits-spleen-volume-reduction-when-added-to-stable-ruxolitinib-in-patients-with-myleofibrosis
10. Navtemadlin | C28H35Cl2NO5S | CID 58573469 - PubChem, accessed September 7, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Navtemadlin
11. Navtemadlin: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 7, 2025, https://go.drugbank.com/drugs/DB15299
12. Safety Data Sheet - MedchemExpress.com, accessed September 7, 2025, https://file.medchemexpress.com/batch_PDF/HY-12296/Navtemadlin-SDS-MedChemExpress.pdf
13. NAVTEMADLIN - Inxight Drugs, accessed September 7, 2025, https://drugs.ncats.io/drug/7R7G6EH5UL
14. Kartos Therapeutics - Navtemadlin - AdisInsight - Springer, accessed September 7, 2025, https://adisinsight.springer.com/drugs/800037243
15. 1352066-68-2|2-((3R,5R,6S)-5-(3-Chlorophenyl) - BLDpharm, accessed September 7, 2025, https://www.bldpharm.com/products/1352066-68-2.html
16. Navtemadlin (AMG 232) CAS:1352066-68-2 - Ruixibiotech, accessed September 7, 2025, https://www.ruixibiotech.com/pts/navtemadlin
17. Navtemadlin 98% | CAS: 1352066-68-2 | AChemBlock, accessed September 7, 2025, https://www.achemblock.com/y230506-navtemadlin.html
18. NB-64-69186-5mg | Navtemadlin [1352066-68-2] Clinisciences, accessed September 7, 2025, https://www.clinisciences.com/-186/navtemadlin-1352066-68-2-24588906.html
19. AMG 232 (Navtemadlin ; KRT-232) | CAS 1352066-68-2 | AbMole BioScience, accessed September 7, 2025, https://www.abmole.com/products/amg-232.html
20. Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9306949/
21. Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma - PMC - PubMed Central, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12402800/
22. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents - AACR Journals, accessed September 7, 2025, https://aacrjournals.org/mct/article/14/3/649/135861/The-MDM2-Inhibitor-AMG-232-Demonstrates-Robust
23. Full article: BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis - Taylor & Francis Online, accessed September 7, 2025, https://www.tandfonline.com/doi/full/10.2217/fon-2022-0901
24. BOREAS: A global phase 3 study of KRT-232, a first-in-class murine ..., accessed September 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS7057
25. Navtemadlin (AMG 232) | MDM2-p53 Interaction Inhibitor | MedChemExpress, accessed September 7, 2025, https://www.medchemexpress.com/AMG-232.html
26. request for project team member application for conducting clinical trials using amg 232, accessed September 7, 2025, https://www.dfhcc.harvard.edu/fileadmin/media/ETCTN/02_Developing_an_ETCTN_Study/PTMA_Requests/AMG23230_Nov2015.pdf
27. Full article: A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1) - Taylor & Francis Online, accessed September 7, 2025, https://www.tandfonline.com/doi/full/10.1080/00498254.2022.2114116
28. Study Details | NCT03041688 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | ClinicalTrials.gov, accessed September 7, 2025, https://clinicaltrials.gov/study/NCT03041688
29. A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1) - Taylor & Francis Online, accessed September 7, 2025, https://www.tandfonline.com/doi/abs/10.1080/00498254.2022.2114116
30. Population Pharmacokinetic Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma or Acute Myeloid Leukemia | Blood | American Society of Hematology, accessed September 7, 2025, https://ashpublications.org/blood/article/134/Supplement_1/5766/425879/Population-Pharmacokinetic-Analysis-of-the-MDM2
31. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: In vitro-in vivo correlation - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/274010772_Pharmacokinetics_and_metabolism_of_AMG_232_a_novel_orally_bioavailable_inhibitor_of_the_MDM2-p53_interaction_in_rats_dogs_and_monkeys_In_vitro-in_vivo_correlation
32. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/25798742/
33. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7783771/
34. Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype. - ASCO Publications, accessed September 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2012
35. Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/40591434/
36. Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma - AACR Journals, accessed September 7, 2025, https://aacrjournals.org/clincancerres/article/31/17/3771/764185/Preclinical-Modeling-of-Navtemadlin
37. Navtemadlin by Kartos Therapeutics for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval - Pharmaceutical Technology, accessed September 7, 2025, https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/
38. Study Details | NCT03662126 | KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | ClinicalTrials.gov, accessed September 7, 2025, https://clinicaltrials.gov/study/NCT03662126
39. Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | ClinicalTrials.gov, accessed September 7, 2025, https://www.clinicaltrials.gov/study/NCT06479135?term=AREA%5BInterventionSearch%5D(NAVTEMADLIN)%20AND%20AREA%5BStudyType%5D(INTERVENTIONAL)&rank=3
40. Research - Kartos Therapeutics, accessed September 7, 2025, https://kartosthera.com/research
41. KRT-232: a novel MDM2 inhibitor approach in myelofibrosis - YouTube, accessed September 7, 2025, https://www.youtube.com/watch?v=u_drC5VAl08
42. Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC). - ASCO Publications, accessed September 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9506
43. Study Details | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | ClinicalTrials.gov, accessed September 7, 2025, https://www.clinicaltrials.gov/study/NCT03787602?term=AREA%5BInterventionSearch%5D(NAVTEMADLIN)%20AND%20AREA%5BStudyType%5D(INTERVENTIONAL)&rank=7
44. ANLL Completed Phase 1 Trials for Navtemadlin (DB15299) | DrugBank Online, accessed September 7, 2025, https://go.drugbank.com/indications/DBCOND0042650/clinical_trials/DB15299?phase=1&status=completed
45. Oncology Completed Phase 1 Trials for Navtemadlin (DB15299) | DrugBank Online, accessed September 7, 2025, https://go.drugbank.com/indications/DBCOND0029318/clinical_trials/DB15299?phase=1&status=completed
46. An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms. | Journal of Clinical Oncology - ASCO Publications, accessed September 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS7063
47. News - navtemadlin (KRT-232) - LARVOL VERI, accessed September 7, 2025, https://veri.larvol.com/news/krt-232/drug
48. Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm, accessed September 7, 2025, https://www.onclive.com/view/navtemadlin-based-therapy-could-drive-change-in-the-myelofibrosis-treatment-paradigm
49. KRT-232-109: Navtemadlin plus ruxolitinib in MF with a suboptimal ruxolitinib response, accessed September 7, 2025, https://mpn-hub.com/medical-information/krt-232-109-navtemadlin-plus-ruxolitinib-in-mf-with-a-suboptimal-ruxolitinib-response
50. Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib - NCI, accessed September 7, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-05880
51. Myelofibrosis KRT-232-115 - Mission Cancer + Blood, accessed September 7, 2025, https://www.missioncancer.com/clinical_trials/myelofibrosis-krt-232-115/
52. A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera | Blood | American Society of Hematology, accessed September 7, 2025, https://ashpublications.org/blood/article/134/Supplement_1/4168/425756/A-Randomized-Open-Label-Multicenter-Phase-2-Study
53. KRT-232 and TKI Study in Chronic Myeloid Leukemia - NCI, accessed September 7, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-12575
54. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic, accessed September 7, 2025, https://www.mayo.edu/research/clinical-trials/cls-20441973
55. An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer. | Journal of Clinical Oncology - ASCO Publications, accessed September 7, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS8600
56. Search Orphan Drug Designations and Approvals - FDA, accessed September 7, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=735120
57. Search for an orphan drug - Orphanet, accessed September 7, 2025, https://www.orpha.net/en/drug/regulatory/628234?name=&mode=®ion=
58. List of MDM2-p53 inhibitors in completed clinical trials | Download ..., accessed September 7, 2025, https://www.researchgate.net/figure/List-of-MDM2-p53-inhibitors-in-completed-clinical-trials_tbl1_357070353
59. Clinical Overview of MDM2/X-Targeted Therapies - Frontiers, accessed September 7, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2016.00007/full